BrainStorm Cell Therapeutics Inc. announced the upcoming publication of a case report on an individual patient treated with the company's NurOwn(TM) cell therapy in "Muscle & Nerve" (John Wiley & Sons). The report, which looked at one patient diagnosed with both Myasthenia Gravis (MG) and Amyotrophic Lateral Sclerosis (ALS) showed significant improvements in both cognitive and motor function following initial and repeat treatments with NurOwn. At 6 months post-transplantation, due to progression of weakness and deterioration in cognition, a repeat injection of Brainstorm's NurOwn, was performed.

Again, improvements in ALSFRS-R and respiratory forced vital capacity (FVC) were observed following second treatment. Treatment with NurOwn appeared safe and well tolerated; the patient did not experience any serious adverse events after either course of treatment. The results suggest that repeated therapy may maintain and enhance the clinical benefits of NurOwn cell therapy in neurological diseases.